Observational study of the clinical efficacy of endoxifen in reducing non-suicidal self-injury (NSSI) behaviors in psychiatric patients

Abstract

Non-suicidal self-injury (NSSI) is a prevalent behavior in patients with various psychiatric disorders, particularly those diagnosed with borderline personality disorder (BPD), major depressive disorder (MDD), and anxiety disorders and its criteria are outlined in DSM 5. There are many modalities for treatment however no clear guidelines exist for NSSI. Endoxifen, a metabolite of tamoxifen, has demonstrated potential in modulating mood and emotional regulation. This observational study explores the efficacy of endoxifen in reducing NSSI behaviors in a psychiatric patient population. Total number of patients who received treatment was 68 in whom endoxifen was used as an adjuvant to other psychiatric medications. Results from a 6-month observational study involving 68 patients showed a significant reduction in the frequency and severity of NSSI behaviors. Side effects were minimal, and treatment adherence was high, suggesting that endoxifen could be an effective treatment option for patients with persistent NSSI behaviors.